Search details
1.
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
J Intern Med
; 291(1): 72-80, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34459525
2.
Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial.
Stroke
; 52(10): 3082-3087, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34465201
3.
Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.
N Engl J Med
; 389(17): 1626-1628, 2023 Oct 26.
Article
in English
| MEDLINE | ID: mdl-37888924
4.
Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.
N Engl J Med
; 387(14): 1333-1336, 2022 10 06.
Article
in English
| MEDLINE | ID: mdl-36103621
5.
Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.
Front Immunol
; 15: 1346749, 2024.
Article
in English
| MEDLINE | ID: mdl-38558811
6.
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Vaccines (Basel)
; 10(3)2022 Feb 24.
Article
in English
| MEDLINE | ID: mdl-35334989
7.
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.
Clin Transl Immunology
; 11(4): e1388, 2022.
Article
in English
| MEDLINE | ID: mdl-35444806
8.
SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.
PLoS One
; 17(1): e0262169, 2022.
Article
in English
| MEDLINE | ID: mdl-35020778
9.
Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.
Immun Inflamm Dis
; 10(4): e595, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35349756
10.
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
EBioMedicine
; 70: 103523, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34391088
11.
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.
Lancet Infect Dis
; 24(2): e80-e81, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38190833
12.
Mucosal IgA protects against BQ.1 and BQ.1.1 infection.
Lancet Infect Dis
; 23(8): e272-e273, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37453441
13.
7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection.
Lancet Infect Dis
; 23(2): 150-152, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36640796
14.
Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden.
Lancet Reg Health Eur
; 33: 100725, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37680234
Results
1 -
14
de 14
1
Next >
>>